Investigation of Early Diagnosis and Treatment for Diabetes Mellitus Type 1
DOI:
https://doi.org/10.54097/ijbls.v2i1.5161Keywords:
Type 1 diabetes, Insulin, Pathology, Diagnostic, Combination treatmentAbstract
Type I diabetes mellitus (TIDM) is a kind of chronic disease, which caused by autoimmune disorders which result in hyperglycemia and inadequate insulin secretion. Over the past 25 years, knowledge about T1DM has advanced rapidly. These recent progressions in researching T1DM help us better understand the disease in various aspects including genetics, epidemiology, immunology, and pancreatic cancer. Epidemiology, immunology, beta cell phenotype, and disease burden. Why is T1DM thought to be preventable? Several areas of diabetes research have been brought together to suggest therapeutic targets. This article introduces T1DM from its basic definition, world impact, pathology, current existing drug-assistant treatment, and now existing diagnostic tools such as OGTT. This article is based on literature across several fields including Medications, Epidemics, and Statistics. Also, several anti-diabetic drugs that have the potential in participating T1DM treatment as assistance were listed as well. For example, metformin has been recognized as having a huge potential in reducing blood sugar level company with insulin. This article mainly focused on showing information about T1DM and attempting to make several predictions on potential treatments that may be helpful for future patients.
Downloads
References
DiMeglio, L. A., Evans-Molina, C., Oram, R. A. (2018). Type 1 diabetes. The Lancet, 391(10138), 2449–2462.
Maahs, D. M., West, N. A., Lawrence, J. M., et al. (2010). Epidemiology of type 1 diabetes. Endocrinology and Metabolism Clinics of North America, 39(3), 481–497.
Gillespie, K. M. (2006). Type 1 diabetes: Pathogenesis and prevention. Canadian Medical Association Journal, 175(2), 165–170.
Avgerinos, I., Manolopoulos, A., Michailidis, T., et al. (2021). Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and Network meta‐analysis. Diabetes, Obesity and Metabolism, 23(3), 822–831.
Alberti, K. G. M. M., Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. part 1: Diagnosis and classification of diabetes mellitus. provisional report of a who consultation. Diabetic Medicine, 15(7), 539–553.
Soltesz, G., Patterson, C. C., Dahlquist, G. (2007). Worldwide childhood type 1 diabetes incidence ? what can we learn from epidemiology? Pediatric Diabetes, 8(s6), 6–14.
Colagiuri, S. (2021). Definition and classification of diabetes and Prediabetes and emerging data on phenotypes. Endocrinology and Metabolism Clinics of North America, 50(3), 319–336.
Warnes, H., Helliwell, R., Pearson, S. M., et al. (2018). Metabolic control in type 1 diabetes: Is adjunctive therapy the way forward? Diabetes Therapy, 9(5), 1831–1851.
Qiu, L., Ling, P., Yang, D., et al. (2020). Current status of metformin in addition to insulin therapy in adult patients with type 1 diabetes mellitus: An analysis from the Guangdong Type 1 diabetes mellitus translational medicine study. Journal of Diabetes, 12(10), 754–760.
Ratner, R. E., Dickey, R., Fineman, M., et al. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabetic Medicine, 21(11), 1204–1212.
Peters, A. L., Buschur, E. O., Buse, J. B., et al. (2015). Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care, 38(9), 1687–1693.
